By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Helicos BioSciences today reported a 43 percent drop in its third quarter revenues.

In a document filed with the US Securities and Exchange Commission, the sequencing technology and diagnostics firm reported that for the three months ended Sept. 30, it recorded $636,000 in revenues, down from $1.1 million in the year-ago period. Product revenues plummeted to $214,000 from $1.1 million, an 81 percent drop-off. Grant revenues rose to $422,000 from $13,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.